ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
108,453.74
5.18%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) 뉴스

REPL

Replimune (REPL)

Replimune Group Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:REPL
일자시간출처헤드라인심볼기업
2025/01/1807:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
2025/01/1106:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
2025/01/0822:00GlobeNewswire Inc.Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsNASDAQ:REPLReplimune Group Inc
2024/12/2322:00GlobeNewswire Inc.Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REPLReplimune Group Inc
2024/12/2107:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
2024/12/1911:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
2024/12/1706:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REPLReplimune Group Inc
2024/12/0422:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:REPLReplimune Group Inc
2024/11/2722:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
2024/11/2707:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:REPLReplimune Group Inc
2024/11/2622:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
2024/11/2613:55GlobeNewswire Inc.Replimune Announces Pricing of Upsized Public OfferingNASDAQ:REPLReplimune Group Inc
2024/11/2521:09GlobeNewswire Inc.Replimune Announces Proposed Public OfferingNASDAQ:REPLReplimune Group Inc
2024/11/2207:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
2024/11/2206:05GlobeNewswire Inc.Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNASDAQ:REPLReplimune Group Inc
2024/11/2111:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
2024/11/2111:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
2024/11/2007:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
2024/11/1421:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:REPLReplimune Group Inc
2024/11/1222:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REPLReplimune Group Inc
2024/11/1222:00GlobeNewswire Inc.Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
2024/11/1003:00GlobeNewswire Inc.Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)NASDAQ:REPLReplimune Group Inc
2024/11/0906:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
2024/10/3022:15GlobeNewswire Inc.Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:REPLReplimune Group Inc
2024/10/1706:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
2024/10/1005:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
2024/10/0121:00GlobeNewswire Inc.Replimune to Present at Two Upcoming Investor ConferencesNASDAQ:REPLReplimune Group Inc
2024/09/1522:45GlobeNewswire Inc.Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
2024/09/0921:00GlobeNewswire Inc.Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024NASDAQ:REPLReplimune Group Inc
2024/09/0605:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
 검색 관련기사 보기:NASDAQ:REPL

최근 히스토리

COIN
ADAUSD
Cardano
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
NYSE
DIS
Walt Disney
FX
USDGBP
US Dollar vs Sterling
USI
USTECH100
US Tech 100
FX
USDEUR
US Dollar vs Euro
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
NYSE
JPM
JP Morgan Chase
NASDAQ
AAPL
Apple
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유